Literature DB >> 3087993

Plasminogen activators and their inhibitors in a human mammary cell line (HBL-100). Modulation by glucocorticoids.

N Busso, D Belin, C Failly-Crépin, J D Vassalli.   

Abstract

Culture of human mammary HBL-100 cells in the presence of dexamethasone, a synthetic glucocorticoid, resulted in opposite effects on the production of the two plasminogen activators (PAs): a decrease in urokinase-type PA (u-PA) and a concomitant increase in tissue-type PA (t-PA). Two PA-specific inhibitors, one related to that produced by bovine aortic endothelial cells, and the other related to that isolated from human placenta, were also produced by these cells; dexamethasone did not affect the production of either of these inhibitors. The glucocorticoid effects observed on PA enzymatic activities were associated with changes in PA mRNA levels. Experiments using inhibitors of RNA and protein synthesis suggested that the glucocorticoid-induced decrease in u-PA mRNA was a secondary event, requiring synthesis of new regulatory proteins; in contrast, the increase in t-PA mRNA appeared to be a direct effect on t-PA gene expression.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3087993

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Urokinase- and tissue-type plasminogen activators are suppressed by cortisol in the involuting prostate of castrated rats.

Authors:  S N Freeman; P S Rennie; J Chao; L R Lund; P A Andreasen
Journal:  Biochem J       Date:  1990-07-01       Impact factor: 3.857

2.  Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury.

Authors:  C Barazzone; D Belin; P F Piguet; J D Vassalli; A P Sappino
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

3.  Glucocorticoid (GC)-mediated down-regulation of urokinase plasminogen activator expression via the serum and GC regulated kinase-1/forkhead box O3a pathway.

Authors:  Travis Pew; Min Zou; Deanna R Brickley; Suzanne D Conzen
Journal:  Endocrinology       Date:  2008-01-31       Impact factor: 4.736

Review 4.  The plasminogen-plasmin system in malignancy.

Authors:  H C Kwaan
Journal:  Cancer Metastasis Rev       Date:  1992-11       Impact factor: 9.264

5.  Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney.

Authors:  A P Sappino; J Huarte; J D Vassalli; D Belin
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 6.  Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Authors:  M Yamamoto; R Sawaya; S Mohanam; V H Rao; J M Bruner; G L Nicolson; K Ohshima; J S Rao
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Variable response of tissue parameters of the fibrinolytic system to unilateral or bilateral adrenalectomy and unilateral or bilateral adrenal demedullation.

Authors:  A Smokovitis; N Kokolis; C Rekkas; T Ploumis
Journal:  J Endocrinol Invest       Date:  1991-11       Impact factor: 4.256

8.  Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2.

Authors:  D Belin; A Wohlwend; W D Schleuning; E K Kruithof; J D Vassalli
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

9.  Protease-nexin I as an androgen-dependent secretory product of the murine seminal vesicle.

Authors:  J D Vassalli; J Huarte; D Bosco; A P Sappino; N Sappino; A Velardi; A Wohlwend; H Ernø; D Monard; D Belin
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

10.  Upregulation of urokinase receptor expression on migrating endothelial cells.

Authors:  M S Pepper; A P Sappino; R Stöcklin; R Montesano; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1993-08       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.